

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
980034.417C1

APPLICANT
Ronald Berenson et al.

FILING DATE
September 20, 2001

APPLICATION NO.
09/960,264

GROUP ART UNIT
1615

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## **U.S. PATENT DOCUMENTS**

	*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILES DATE IF APEROPRIATE
1/4	B AA 5,190,8°		5,190,878	03/02/93 Wilhelm		435	285	
		AB	5,858,358	01/12/99	June et al.	424	130.1	
		AC	5,888,807	03/30/99	Palsson et al.	435	293.2	
		AD	5,985,653	11/16/99	Armstrong et al.	435	303.1	
	/	AE	6,096,532	08/01/00	Armstrong et al.	435	286.5	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
			COONIKI	YES	NO
AF					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		OTTENTAL (Including Author, Title, Date, 1 ertinent 1 ages, Dic.)
W	AG	Bretscher, P., "The two-signal model of lymphocyte activation twenty-one years later," <i>Immunology Today 13</i> (2): 74-76, 1992.
	AH	Garland et al., "The use of Teflon cell culture bags to expand functionally active CD8 <sup>+</sup> cytotoxic T lymphocytes," <i>Journal of Immunological Methods 227</i> : 53-63, 1999.
	AI	Haanen et al., "Selective Expansion of Cross-reactive CD8 <sup>+</sup> Memory T Cells by Viral Variants," <i>J. Exp. Med. 190</i> (9): 1319-1328, November 1, 1999.
	AJ	Iezzi et al., "The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells," <i>Immunity 8</i> : 89-95, January 1998.
	AK	June et al., "The B7 and CD28 receptor families," Immunology Today 15(7): 321-331, 1994.
	AL	Kato et al., "Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> 101(5): 1133-1141, March 1998.
1	AM	Krawczyk et al., "Cbl-b Is a Negative Regulator of Receptor Clustering and Raft Aggregation in T Cells," <i>Immunity 13</i> : 463-473, October 2000.
J	AN	Liebowitz et al., "Costimulatory approaches to adoptive immunotherapy," <i>Current Opinion in Oncology 10</i> : 533-541, 1998.

EXAMINER

LANIRORP

DATE CONSIDERED /27/3

\* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

OIPE	٠ - ا		8								
- 631	900	<u> </u>			^.				Sheet	<u>2</u> of <u>:</u>	
FQKM PTO-14 (REV.7-80)	49		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. APPLICATION NO. 980034.417C1 09/960,264			10	IPE	
AL THINK	<b>ORM</b>	ATION DISCLOSU		1ENT	APPLICANT Ronald Berenson et a	 al		(	nrī	0 3 20	
		(Use several sheets if ned	cessary)		FILING DATE September 20, 2001 GROUP ART UNI 1615						
ı			U.S	. PATENT I	DOCUMENTS		101		- VE	ADEM	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	ss	SUBCLASS	FILIN	IG DATE	
	ВА								IF AFF	KOPKIATE	
	ВВ										
	ВС								=	ri E	
	BD								OH C		
	BE									H .	
	BF						_		- 5	1800/s	
	BG								1600/2900		
			FOREI	GN PATEN'	T DOCUMENTS		1	<del></del>		<u></u>	
		DOCUMENT NUMBER	DATE		COUNTRY					LATION	
	ВН								YES	NO	
	ВІ										
	ВЈ										
		OTHER	PRIOR AI	RT (Including A	uthor, Title, Date, Pertinent Page	on Ftc.)		1			
BC	ВК	Ranheim and R Leukemic B Co	Kipps, "Act	tivated T Cel	Ils Induce Expression of the pendent Signal," J. Exp	of B7/	BB1 d. 17	on Norma 77: 925-93	al or 5, Api	 ril	
	_	1993.	1993.								
1	BL	Expressing Bot	Ten Berge et al., "Selective Expansion of a Peripheral Blood CD8 <sup>+</sup> Memory T Cell Subset Expressing Both Granzyme B and L-Selectin During Primary Viral Infection in Renal Allograft Recipients," <i>Transplantation Proceedings 30</i> : 3975-3977, 1998.								
	ВМ		nents, 17a	<u>nspiuniaii0r</u>	i Froceeaings 30: 397	<u> 3-397</u>	/, 19	98.			

**EXAMINER** 

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

ANKRORD

BN

во

(REV.7-80)	E		. DEPARTMENT OF TENT AND TRADE		ATTY. DOCKET NO. 980034.417C1		APPLICATION NO. 09/960. <b>3</b> 64	1				
	1/2	)			APPLICANTS		09/960,364	TAP O				
MAR 3 1	2003 IN	CRMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)			Ronald Berenson et al.		·/C^ /					
12	j.	2/2	,,		FILING DATE September 20, 2001	1	GROUP ART UNIT	Ĉ,	700;			
TRADE	MARK	<del>,                                      </del>	U.S.	. PATENT	DOCUMENTS		1013	100	0/200			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILINC IF APPRO	DATE OPRIATE			
BU	AA	5,735,279	5,735,279 04/07/98 Klavenes			128	654					
	AB	5,962,319	5,962,319 10/05/99 Ogawa e		al.	435	325					
<b>√</b>	AC	6,352,694	03/05/02	June et al.		424	93.71					
	<b>,</b>		FOREI	GN PATEN	T DOCUMENTS							
		DOCUMENT NUMBER	DATE		COUNTRY			TRANSLATION YES NO				
W	AD	WO 97/01304	01/16/97	WIPO			· · ·					
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent i	Pages, Etc.)						
	AE				n Autologous T Cell		nerapy Appro	ach for	r			
111/		Treating B-C	Treating B-Cell Lymphocytic Leukemia (B-CLL)," in <i>Proceedings of the 42<sup>nd</sup> Annual</i>									
Vy		Meeting of the American Society of Hematology, San Francisco, December										
		96, no. 11, pa	urt 1, ABSTI	RACT # 36	16.	•	,	.,				
	AF	Creson, J. et	Creson, J. et al., "The Mode and Duration of Anti-CD28 Costimulation Determine									
			Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus									
		Type 1 in Vit	ro," <i>Journal</i>	Of Virolog	y, 73(11):9337-9347	, Novemb	er 1999.					
	AG		Hami, L. et al., "Xcellerate <sup>TM</sup> : A Platform Process for the GMP Manufacture of Activated									
		Cells for the	Treatment of	f Patients w	rith Cancer and Immu	ine Dysfu	nction," in Pi	oceed	ings			
		of the 42 <sup>nd</sup> An	inual Meetin	g of the An	nerican Society of He	matology.	, San Francisc	co,	0			
					part 1, abstract # 363		•					
	AH	•			ent of Freshly Harves		opreserved >	Celler	ate <sup>TM</sup>			
					ations," in <i>Proceedir</i>							
					, San Francisco, Dece							
		part 2, abstrac			,		, , , , , , , , , , , ,	-,	,			
	AI	Larsson, S. et	al., "Produc	tive Cytom	egalovirus (CMV) In	fection E	xclusively in	CD13-	_			
	·"				ear Cells from CMV-			0213				
					ruary 15, 1998.	1111000001	inar viadais,					
	AJ				Closed, Scalable Proc	ess for the	GMP Manu	facture				
	^								, 01			
$\sqrt{I}$			Stable Activated T Cells," in <i>Proceedings of the 15<sup>th</sup> Annual Scientific Meeting of the Society for Biological Therapy</i> , Seattle, October 26-29, 2000, and <i>Journal of</i>									
<i>Immunotherapy</i> , (23)5:599, September 2000.												
EXAMINE	R	1			DATE CONSIDERED		· · · · · · · · · · · · · · · · · · ·					
	(	ANKSOR			<u> </u>	7/2	>					
EXAMINE		nitial if reference considere	d, whether or not o	criteria is in conf	ormance with MPEP 609. Dra	w line through	citation if not in					

Date: 03/24/03

1	_								
<i>k</i>	6	IPE VOIS						Sheet	<u>1</u> of <u>1</u>
FORM PTO-144 (REV.7-80)					ATTY. DOCKET NO. APPLICATION NO. 980034.417C1 09/960,264				
	\. JI	IN 0 9 2003 👸 PA			980034.417C1 APPLICANTS		_		
`	T.	FORMATION SCLOSUR	E STATEMENT		Roanld Berenson et al	l			
		A characteristic of ne	ecessary)		FILING DATE September 20, 2001		ROUP ART UNIT		
	_		U.S	S. PATENT	DOCUMENTS		615		
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		G DATE ROPRIATE
M	AA	5,837,477	11/17/98	Germain	et al.	435	7.24	II ALL	OFRIATE
d_	AB	5,942,607	08/24/99	Freeman o	et al.	536	23.5		-
	AC					R	ECC"		
	AD					~ JI	ECEIVE W 1 1 2003	D	
	AE					ECHC	1 1 2003		
	AF					- 02	WER 1600/	ľű o .	_
	AG							90 <u>0</u>	
	AH								
	AI								
	AJ								
			FOREI	GN PATEN	T DOCUMENTS				
		DOCUMENT NUMBER	DATE DATE		COUNTRY		TRANSI	LATION NO	
	AK				-				
	AL								
	AM								
	AN								
	AO								
		ОТНЕ	R PRIOR A	RT (Including A	luthor, Title, Date, Pertinent I	Pages, Etc.)			
	AP					1811, 2017			
	AQ								
	AR							<del></del>	
EXAMINE	~ /	AWKLORD		]	DATE CONSIDERE	22/2			
EXAMINE		itial if reference considere	d, whether or not	criteria is in conf	ormance with MPFP 609 Dr.	aw line through	citation if not in		
	cc	mormance and not consider	nered. Include cor	y of this form wi	th next communication to app	licant(s).			

Date: 06/04/03